Q-omics provides the consensus-scored GRIN3A profile across patient tissues and cancer cell-line models. GRIN3A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRIN3A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GRIN3A RNA expression shows 19,465 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where GRIN3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN3A survival associations across molecular data types. GRIN3A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN3A RNA expression–survival associations across cancer types. High GRIN3A expression shows unfavorable associations in ACC and UVM, but favorable associations in HNSC, SKCM, LGG and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRIN3A RNA expression.
This table summarizes GRIN3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIN3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN3A shows lower tumor expression in COAD, THCA, BRCA and UCEC and higher tumor expression in STAD and LIHC. The COAD box plot shows higher GRIN3A RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p < 0.001).
This table shows molecular features associated with GRIN3A in patient tissues and cancer cell lines. In patient samples, GRIN3A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
